Bevacizumab-irinotecan data hold up in recurrent GBM: Comment
Publication
, Journal Article
Friedman, HS
Published in: Oncology Report
July 1, 2010
Duke Scholars
Published In
Oncology Report
EISSN
1548-5323
ISSN
1548-5323
Publication Date
July 1, 2010
Issue
JULY-AUGUST
Start / End Page
4
Related Subject Headings
- Oncology & Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Friedman, H. S. (2010). Bevacizumab-irinotecan data hold up in recurrent GBM: Comment. Oncology Report, (JULY-AUGUST), 4.
Friedman, H. S. “Bevacizumab-irinotecan data hold up in recurrent GBM: Comment.” Oncology Report, no. JULY-AUGUST (July 1, 2010): 4.
Friedman HS. Bevacizumab-irinotecan data hold up in recurrent GBM: Comment. Oncology Report. 2010 Jul 1;(JULY-AUGUST):4.
Friedman, H. S. “Bevacizumab-irinotecan data hold up in recurrent GBM: Comment.” Oncology Report, no. JULY-AUGUST, July 2010, p. 4.
Friedman HS. Bevacizumab-irinotecan data hold up in recurrent GBM: Comment. Oncology Report. 2010 Jul 1;(JULY-AUGUST):4.
Published In
Oncology Report
EISSN
1548-5323
ISSN
1548-5323
Publication Date
July 1, 2010
Issue
JULY-AUGUST
Start / End Page
4
Related Subject Headings
- Oncology & Carcinogenesis